Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
News|Articles|July 30, 2026
Testosterone deficiency: FAQs from the AUA guideline
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A reference on the key recommendations from the AUA Testosterone Deficiency guideline.
Advertisement
Advertisement
Testosterone deficiency has become a subject of national discussion in recent months. In July 2026, the US Department of Defense (DoD) announced it would begin annual testosterone deficiency screening for active-duty service members 30 years and older, with voluntary testing available to younger troops and testosterone replacement therapy (TRT) offered to those who screen positive and choose treatment.1
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement